Liraglutide attenuates gefitinib-induced cardiotoxicity and promotes cardioprotection through the regulation of MAPK/NF-κB signaling pathways

Gefitinib is an effective treatment for patients with locally advanced non-small cell lung cancer. However, it is associated with cardiotoxicity that can limit its clinical use. Liraglutide, a glucagon-like peptide 1 receptor agonist, showed potent cardioprotective effects with the mechanism is yet...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Saudi Pharm J
Päätekijät: AlAsmari, Abdullah F., Ali, Nemat, AlAsmari, Fawaz, AlAnazi, Wael A., AlShammari, Musaad A., Al-Harbi, Naif O., Alhoshani, Ali, As Sobeai, Homood M., AlSwayyed, Mohammed, AlAnazi, Mohammed M., AlGhamdi, Nader S.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Elsevier 2020
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7132601/
https://ncbi.nlm.nih.gov/pubmed/32273812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jsps.2020.03.002
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia